Cardiac safety of liposomal anthracyclines

Cardiovasc Toxicol. 2007;7(2):72-4. doi: 10.1007/s12012-007-0014-4.

Abstract

Anthracyclines remain amongst the most active therapeutic agents for breast cancer treatment. Rather than being supplanted by novel targeted agents, they are being combined with them in various schedules. Furthermore, anthracyclines themselves are still being studied, with increasing biological understanding of their biological activity and molecular targets. A cardiac safe formulation of doxorubicin opens a number of interesting therapeutic opportunities. Liposomal doxorubicins appear to provide this opportunity.

Publication types

  • Review

MeSH terms

  • Adult
  • Aged
  • Anthracyclines / administration & dosage*
  • Anthracyclines / adverse effects*
  • Antibiotics, Antineoplastic / administration & dosage*
  • Antibiotics, Antineoplastic / adverse effects*
  • Clinical Trials, Phase II as Topic
  • Doxorubicin / administration & dosage
  • Doxorubicin / adverse effects
  • Excipients
  • Female
  • Heart Diseases / chemically induced*
  • Heart Diseases / pathology
  • Humans
  • Liposomes
  • Male
  • Middle Aged
  • Polyethylene Glycols

Substances

  • Anthracyclines
  • Antibiotics, Antineoplastic
  • Excipients
  • Liposomes
  • Polyethylene Glycols
  • Doxorubicin